AAAAAA

   
Results: 1-25 | 26-34
Results: 1-25/34
A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/
Authors: AAMDAL S DOMBERNOWSKY P WANDERS J CAPRIATI A LUND B
Citation: S. Aamdal et al., A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/, Annals of oncology, 9, 1998, pp. 656-656
COMMON TOXICITY CRITERIA (CTC) VERSION 2.0 - HIGHLIGHTS AND TOOLS
Authors: ARBUCK SG IVY P SETSER A EISENHAUER E WANDERS J
Citation: Sg. Arbuck et al., COMMON TOXICITY CRITERIA (CTC) VERSION 2.0 - HIGHLIGHTS AND TOOLS, Annals of oncology, 9, 1998, pp. 35-35
EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED
Authors: THERASSE P EISENHAUER E WANDERS J VERWEIJ J VANGLABBEKE M VANOOSTEROM AT KAPLAN RS CHRISTIAN MC GWYTHER S ARBUCK SG
Citation: P. Therasse et al., EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED, Annals of oncology, 9, 1998, pp. 66-66
A PHASE-II STUDY WITH GI147211 (GW211) IN SMALL-CELL LUNG-CANCER (SCLC)
Authors: SESSA C WANDERS J DOMBERNOWSKY P NIELSEN D MORANT R DRINGS P WISSEL P HANAUSKE AR
Citation: C. Sessa et al., A PHASE-II STUDY WITH GI147211 (GW211) IN SMALL-CELL LUNG-CANCER (SCLC), Annals of oncology, 9, 1998, pp. 255-255
A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF LU-79553 ADMINISTEREDEVERY 21 OR 42 DAYS IN PATIENTS (PTS) WITH SOLID TUMORS - AN EORTC-ECSG STUDY
Authors: AWADA A THODTMANN R PICCART MJ DIEU M BARTHOLOMEUS S HOPPENER F WANDERS J VONBROEN IM HANAUSKE AR
Citation: A. Awada et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF LU-79553 ADMINISTEREDEVERY 21 OR 42 DAYS IN PATIENTS (PTS) WITH SOLID TUMORS - AN EORTC-ECSG STUDY, Annals of oncology, 9, 1998, pp. 470-470
A PHASE-I TRIAL OF D19575, A BETA-D-GLUCOSE-LINKED ISOPHOSPHORAMIDE MUSTARD GIVEN AS A 6-HOUR INFUSION
Authors: BRIASOULIS E JUDSON I PAVLIDIS N BEALE P WANDERS J GROOT Y VEERMAN G LOCHER M SCHUESSLER M TZAMAKOU E RAMMOU D WOLF L WALKER R HANAUSKE A
Citation: E. Briasoulis et al., A PHASE-I TRIAL OF D19575, A BETA-D-GLUCOSE-LINKED ISOPHOSPHORAMIDE MUSTARD GIVEN AS A 6-HOUR INFUSION, Annals of oncology, 9, 1998, pp. 473-473
CONDUCTING PHASE-I CLINICAL-TRIAL IN BINARY TREATMENT MODALITY METHODICAL QUESTIONS FOR THE EVALUATION OF BORON NEUTRON-CAPTURE THERAPY
Authors: SAUERWEIN W HIDEGHETY K DEVRIES M WANDERS J GABEL D FANKHAUSER H HUISKAMP R
Citation: W. Sauerwein et al., CONDUCTING PHASE-I CLINICAL-TRIAL IN BINARY TREATMENT MODALITY METHODICAL QUESTIONS FOR THE EVALUATION OF BORON NEUTRON-CAPTURE THERAPY, Annals of oncology, 9, 1998, pp. 494-494
PHASE-II WITH UFT PLUS FOLINIC ACID (FA) IN PATIENTS WITH METASTATIC GASTRIC-CANCER
Authors: RAVAUD A BORNER M SCHELLENS JHM GEOFFROIS L SCHOFFSKI P WANDERS J HANAUSKE AR
Citation: A. Ravaud et al., PHASE-II WITH UFT PLUS FOLINIC ACID (FA) IN PATIENTS WITH METASTATIC GASTRIC-CANCER, Annals of oncology, 9, 1998, pp. 626-626
A PHASE-II STUDY WITH CARZELESIN IN NON-HODGKINS-LYMPHOMA (NHL)
Authors: SORIO R WANDERS J COMELLA G DITTRICH C DROZ JP MORANT R COGNETTI F HANAUSKE AR
Citation: R. Sorio et al., A PHASE-II STUDY WITH CARZELESIN IN NON-HODGKINS-LYMPHOMA (NHL), Annals of oncology, 9, 1998, pp. 674-674
A PHASE-II STUDY WITH GI147211 IN OVARIAN-CANCER
Authors: WANDERS J VANOOSTEROM AT GORE M CALVERT AH HUININK WWT HANSEN HH WISSEL P HANAUSKE AR
Citation: J. Wanders et al., A PHASE-II STUDY WITH GI147211 IN OVARIAN-CANCER, European journal of cancer, 33, 1997, pp. 528-528
PHASE-II STUDIES WITH GI147211 (GI) IN BREAST (B), COLORECTAL (C) ANDNON-SMALL-CELL LUNG-CANCER (N)
Authors: WANDERS J HUININK WWT PAVLIDIS N KAYE SB SESSA C LEHNERT M PICCART M PARIDAENS R WISSEL P HANAUSKE AR
Citation: J. Wanders et al., PHASE-II STUDIES WITH GI147211 (GI) IN BREAST (B), COLORECTAL (C) ANDNON-SMALL-CELL LUNG-CANCER (N), European journal of cancer, 33, 1997, pp. 705-705
CLINICAL AND PHARMACOKINETIC EVALUATION OF THE NEW BISNAPHTALAMIDE LU-79553 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS - AN EORTC ECSG STUDY/
Authors: THODTMANN R AWADA A PICCART M HOPPENER F WANDERS J VONBROEN IM HANAUSKE AR
Citation: R. Thodtmann et al., CLINICAL AND PHARMACOKINETIC EVALUATION OF THE NEW BISNAPHTALAMIDE LU-79553 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS - AN EORTC ECSG STUDY/, European journal of cancer, 33, 1997, pp. 1106-1106
TOPOTECAN, A NEW ACTIVE-DRUG IN THE 2ND-LINE TREATMENT OF SMALL-CELL LUNG-CANCER - A PHASE-II STUDY IN PATIENTS WITH REFRACTORY AND SENSITIVE DISEASE
Authors: ARDIZZONI A HANSEN H DOMBERNOWSKY P GAMUCCI T KAPLAN S POSTMUS P GIACCONE G SCHAEFER B WANDERS J VERWEIJ J
Citation: A. Ardizzoni et al., TOPOTECAN, A NEW ACTIVE-DRUG IN THE 2ND-LINE TREATMENT OF SMALL-CELL LUNG-CANCER - A PHASE-II STUDY IN PATIENTS WITH REFRACTORY AND SENSITIVE DISEASE, Journal of clinical oncology, 15(5), 1997, pp. 2090-2096
ZENIPLATIN IN ADVANCED MALIGNANT-MELANOMA AND RENAL-CANCER - PHASE-IISTUDIES WITH UNEXPECTED NEPHROTOXICITY
Authors: AAMDAL S BRUNTSCH U KERGER J VERWEIJ J HUININK WT WANDERS J RASTOGI R FRANKLIN HR KAYE SB
Citation: S. Aamdal et al., ZENIPLATIN IN ADVANCED MALIGNANT-MELANOMA AND RENAL-CANCER - PHASE-IISTUDIES WITH UNEXPECTED NEPHROTOXICITY, Cancer chemotherapy and pharmacology, 40(5), 1997, pp. 439-443
PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF CARZELESIN (U-80244) GIVEN DAILY FOR 5 CONSECUTIVE DAYS
Authors: WOLFF I BENCH K BEIJNEN JH BRUNTSCH U CAVALLI F DEJONG J GROOT Y VANTELLINGEN O WANDERS J SESSA C
Citation: I. Wolff et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF CARZELESIN (U-80244) GIVEN DAILY FOR 5 CONSECUTIVE DAYS, Clinical cancer research, 2(10), 1996, pp. 1717-1723
MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN
Authors: MCLEOD HL MURRAY LS WANDERS J SETANOIANS A GRAHAM MA PAVLIDIS N HEINRICH B HUININK WWT WAGENER DJT AAMDAL S VERWEIJ J
Citation: Hl. Mcleod et al., MULTICENTER PHASE-II PHARMACOLOGICAL EVALUATION OF RHIZOXIN, British Journal of Cancer, 74(12), 1996, pp. 1944-1948
PHASE-II CLINICAL-TRIALS WITH RHIZOXIN IN BREAST-CANCER AND MELANOMA
Authors: HANAUSKE AR CATIMEL G AAMDAL S HUININK WT PARIDAENS R PAVLIDIS N KAYE SB TEVELDE A WANDERS J VERWEIJ J
Citation: Ar. Hanauske et al., PHASE-II CLINICAL-TRIALS WITH RHIZOXIN IN BREAST-CANCER AND MELANOMA, British Journal of Cancer, 73(3), 1996, pp. 397-399
PHASE-II STUDY OF RHIZOXIN IN SQUAMOUS-CELL HEAD AND NECK-CANCER
Authors: VERWEIJ J WANDERS J GIL T SCHOFFSKI P CATIMEL G TEVELDE A DEMULDER PHM
Citation: J. Verweij et al., PHASE-II STUDY OF RHIZOXIN IN SQUAMOUS-CELL HEAD AND NECK-CANCER, British Journal of Cancer, 73(3), 1996, pp. 400-402
SINGLE-AGENT ACTIVITY OF RHIZOXIN IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL OF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: KAPLAN S HANAUSKE AR PAVLIDIS N BRUNTSCH U TEVELDE A WANDERS J HEINRICH B VERWEIJ J
Citation: S. Kaplan et al., SINGLE-AGENT ACTIVITY OF RHIZOXIN IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL OF THE EORTC EARLY CLINICAL-TRIALS GROUP, British Journal of Cancer, 73(3), 1996, pp. 403-405
DOCETAXEL - AN ACTIVE NEW DRUG FOR TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER
Authors: PICCART MJ GORE M HUININK WTB VANOOSTEROM A VERWEIJ J WANDERS J FRANKLIN H BAYSSAS M KAYE S
Citation: Mj. Piccart et al., DOCETAXEL - AN ACTIVE NEW DRUG FOR TREATMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER, Journal of the National Cancer Institute, 87(9), 1995, pp. 676-681
PHASE-II STUDY OF TOPOTECAN IN REFRACTORY AND SENSITIVE SMALL-CELL LUNG-CANCER (SCLC)
Authors: ARDIZZONI A HANSEN HH DOMBERNOWSKY P KAPLAN S POSTMUS PE GAMUCCI T SCHAEFER B WANDERS J VERWEIJ J
Citation: A. Ardizzoni et al., PHASE-II STUDY OF TOPOTECAN IN REFRACTORY AND SENSITIVE SMALL-CELL LUNG-CANCER (SCLC), European journal of cancer, 31A, 1995, pp. 84-84
PHASE-II STUDIES WITH EO9 IN BREAST, COLORECTAL, GASTRIC, PANCREATIC AND NSCLC
Authors: WANDERS J PAVLIDIS N GAMUCCI T HUININK WWT DIRIX L WOLFF I VERWEIJ J
Citation: J. Wanders et al., PHASE-II STUDIES WITH EO9 IN BREAST, COLORECTAL, GASTRIC, PANCREATIC AND NSCLC, European journal of cancer, 31A, 1995, pp. 565-565
TOPOTECAN IN COLORECTAL-CANCER - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: CREEMERS GJ WANDERS J GAMUCCI T VALLENTIN S DIRIX LY SCHOFFSKI P HUDSON I VERWEIJ J
Citation: Gj. Creemers et al., TOPOTECAN IN COLORECTAL-CANCER - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP, Annals of oncology, 6(8), 1995, pp. 844-846
ACTIVITY OF DOCETAXEL (TAXOTERE) IN SMALL-CELL LUNG-CANCER
Authors: SMYTH JF SMITH IE SESSA C SCHOFFSKI P WANDERS J FRANKLIN H KAYE SB
Citation: Jf. Smyth et al., ACTIVITY OF DOCETAXEL (TAXOTERE) IN SMALL-CELL LUNG-CANCER, European journal of cancer, 30A(8), 1994, pp. 1058-1060
DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP
Authors: AAMDAL S WOLFF I KAPLAN S PARIDAENS R KERGER J SCHACHTER J WANDERS J FRANKLIN HR VERWEIJ J
Citation: S. Aamdal et al., DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP, European journal of cancer, 30A(8), 1994, pp. 1061-1064
Risultati: 1-25 | 26-34